8-K
Current Report
Atara Biotherapeutics, Inc. Filed Acc 0000950170-22-015519
Material agreement · Results of operations · Exit or restructuring costs · Executive or director change
- Item 1.01 Entry into a material definitive agreement
- Item 2.02 Results of operations and financial condition
- Item 2.05 Costs associated with exit or disposal activities
- Item 5.02 Departure or appointment of directors or officers
From the SEC's structured data for this filing
Loading atra-20220802.htm…